Aclaris Therapeutics Inc (FRA:8AT)
€ 0.941 0.0414 (4.6%) Market Cap: 67.77 Mil Enterprise Value: -41.80 Mil PE Ratio: 0 PB Ratio: 0.52 GF Score: 58/100

Aclaris Therapeutics, Inc. - Special Call Transcript

Jul 30, 2019 / 09:00PM GMT
Release Date Price: €1.53 (+0.34%)
Operator

Good day, ladies and gentlemen, and welcome to the Aclaris presents top line data from AUAT-201 Oral phase II trials. (Operator Instructions) As a reminder, this conference call may be recorded for replay purposes. It is now my pleasure to hand the conference to Ms. Kamil Ali-Jackson. Ma'am, you may begin.

Kamil Ali;Jackson
Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued a press release announcing results from AUAT-201 Oral phase II clinical trial for ATI-501, an investigational oral Janus Kinase (JAK)1/3 inhibitor. For those of you who have not seen the press release yet, you will find the release posted in the Investors section of our website at www.aclaristx.com. Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; and Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot